Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

COMPLETED

Identifier: CI-TRIAL-00011857
Entity page: /trial/NCT00454480 ↗
Edges: 13

Neighbours: 2 cancers11 drugs
Drawn: 13 of 13 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes condition of …CONDITION_OFderived2 of 2
← condition of	Leukemia registry condition “Leukemia” mapped ONTOLOGY_EXACT	—	—	Leukemia	1	Observed	clinicaltrials	graph →
← condition of	Myelodysplastic Syndrome registry condition “Myelodysplastic Syndromes” mapped ALIAS	—	—

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes intervention of …INTERVENTION_OFderived11 of 11
← intervention of	Alemtuzumabmonoclonal antibody registry intervention “alemtuzumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Arsenic Trioxidesmall molecule registry intervention “arsenic trioxide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Azacitidinesmall molecule registry intervention “azacitidine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Busulfansmall molecule registry intervention “busulfan” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Clofarabinesmall molecule registry intervention “clofarabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cytarabinesmall molecule registry intervention “cytarabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Daunorubicinsmall molecule registry intervention “daunorubicin hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Fludarabinesmall molecule registry intervention “fludarabine phosphate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemtuzumab Ozogamicinadc registry intervention “gemtuzumab ozogamicin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Melphalansmall molecule registry intervention “melphalan” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Tipifarnibsmall molecule registry intervention “tipifarnib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes intervention of …INTERVENTION_OFderived11 of 11

← intervention of

Alemtuzumabmonoclonal antibody

registry intervention “alemtuzumab” (BIOLOGICAL) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Arsenic Trioxidesmall molecule

registry intervention “arsenic trioxide” (DRUG) mapped ALIAS

—